Top Ten most popular articles on Pharmafile.com this week

pharmafile | December 11, 2020 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, COVID-19, Pfizer, Vaccine, pharma, top 10 

With just around three weeks until the end of a long year, rapidly emerging news around the leading COVID-19 vaccine candidates continues to dominate. The Pfizer/BioNTech vaccine continues to lead the pack, having been approved for emergency use in the UK earlier this week. However, experts have warned that the therapy could cause an allergic reaction in some patients, while the candidate has even attracted the attention of hacker groups. 

Check out the week’s ten most popular articles on Pharmafile.com now!

10. Novartis’ Kisqali delays need for chemo by over 4 years in post-menopausal HR+HER2- metastatic breast cancer

According to Novartis, these were the longest survival data ever reported in this patient population.

9. IBM uncovers “precision phishing campaign” targeting global COVID-19 vaccine cold chain supply

IBM’s team reported that phishing emails were delivered in six countries around the world under the identity of an executive at Chinese cold chain provider Haier Biomedical, with the goal of gathering intelligence on the workings of the global COVID-19 vaccine supply line.

8. NICE recommendation for AstraZeneca’s Calquence in chronic lymphocytic leukaemia populations

For 30 days following the ruling, patients in these populations will be able to access the drug immediately via the NHS in England and Wales, thanks to an interim funding arrangement between AstraZeneca and NHS England.

7. NICE authorises Takeda’s Alunbrig for ALK-positive advanced non-small cell lung cancer

Patients in England, Wales and Northern Ireland within this patient population will now be able to access the drug via the NHS.

6. US pharma lobby launches legal action against the Trump administration over drug pricing proposals

The lobby groups attacked the new proposals on the basis that they are illegal, as they do not take into account any consultation with key stakeholders.        

5. Six-year follow-up data shows Imbruvica’s benefit in high-risk chronic lymphocytic leukaemia

“These large integrated datasets with follow-up up to six years, in addition to other data presented at the meeting in similar populations, contribute to the accumulating evidence supporting the clinically meaningful, long-term treatment benefit of ibrutinib as first-line therapy for patients with CLL.”

4. Novartis unveils new multi-trial data for CAR-T therapy Kymriah in advanced lymphoma

In one 40-month median follow-up study, one third of patients with relapsed or refractory diffuse large B-cell lymphoma receiving Kymriah saw their disease halted for at least two years.

3. MHRA warns patients with history of significant allergic reactions not to receive Pfizer/BioNTech COVID-19 vaccine

“As a precautionary measure, the MHRA has issued temporary guidance to the NHS while it conducts an investigation in order to fully understand each case and its causes,” the MHRA said in a statement. “Pfizer and BioNTech are supporting the MHRA in the investigation.”

2. Hackers breach EMA server to steal data on Pfizer/BioNTech’s COVID-19 vaccine

The hackers managed to access regulatory submission documents relating to the vaccine that were stored on an EMA server.

1. AstraZeneca and Oxford Uni vaccine is safe and effective in preventing COVID-19 infection, Phase 3 data show

21 days following initial dosing, ten patients were hospitalised with COVID-19 infection, with two severe cases and one patient death. None of these cases occurred in the vaccine group. 

Related Content

NICE recommends Pfizer’s rimegepant for preventing episodic migraine attacks

The National Institute for Health and Care Excellence (NICE) has announced that it has recommended …

FDA approves Pfizer’s RSV vaccine for older adults

Global pharmaceutical company Pfizer has announced that the US Food and Drug Administration (FDA) has …


AstraZeneca’s Ultomiris approved in Japan for prevention of relapses in patients with NMOSD

AstraZeneca has announced that Ultomiris (ravulizumab) has been approved in Japan as a long-acting C5 …

Latest content